Hims & Hers Health, Inc. (NYSE:HIMS) Given Consensus Recommendation of "Hold" by Brokerages

Shares of Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) have earned a consensus recommendation of "Hold" from the thirteen brokerages that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $38.00.

A number of brokerages have recently issued reports on HIMS. TD Cowen lowered shares of Hims & Hers Health from a "buy" rating to a "hold" rating and lowered their target price for the company from $44.00 to $30.00 in a research note on Tuesday, April 29th. Canaccord Genuity Group boosted their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research report on Wednesday, February 19th. Wall Street Zen lowered shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a research report on Saturday. Citigroup reiterated a "sell" rating and issued a $30.00 price target (up previously from $25.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Finally, Morgan Stanley dropped their price objective on Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating on the stock in a research note on Tuesday, April 29th.

Hims & Hers Health Stock Down 3.0%

NYSE:HIMS traded down $1.71 during mid-day trading on Monday, hitting $55.15. 38,232,363 shares of the stock traded hands, compared to its average volume of 20,824,183. Hims & Hers Health has a 52 week low of $13.47 and a 52 week high of $72.98. The stock has a market capitalization of $12.35 billion, a price-to-earnings ratio of 125.35 and a beta of 2.09. The firm's 50 day moving average is $42.75 and its two-hundred day moving average is $37.55.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $586.01 million for the quarter, compared to analysts' expectations of $535.21 million. During the same quarter in the prior year, the firm posted $0.05 earnings per share. The company's quarterly revenue was up 110.7% on a year-over-year basis. As a group, research analysts predict that Hims & Hers Health will post 0.29 EPS for the current year.

Insider Activity

In other Hims & Hers Health news, CEO Andrew Dudum sold 128,127 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $33.98, for a total value of $4,353,755.46. Following the completion of the transaction, the chief executive officer now owns 173,655 shares of the company's stock, valued at approximately $5,900,796.90. This trade represents a 42.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Soleil Boughton sold 3,236 shares of the business's stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $27.77, for a total value of $89,863.72. Following the completion of the transaction, the insider now directly owns 170,285 shares of the company's stock, valued at approximately $4,728,814.45. This trade represents a 1.86% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 622,467 shares of company stock worth $25,513,488. 13.71% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in Hims & Hers Health by 11.1% during the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock valued at $489,817,000 after purchasing an additional 2,020,722 shares in the last quarter. Farallon Capital Management LLC boosted its holdings in Hims & Hers Health by 64,338.5% in the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after purchasing an additional 8,364,000 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Hims & Hers Health by 29.0% during the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock worth $168,079,000 after purchasing an additional 1,562,302 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in Hims & Hers Health by 192.0% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock valued at $152,436,000 after buying an additional 4,145,305 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Hims & Hers Health by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company's stock valued at $104,724,000 after acquiring an additional 40,447 shares during the period. Hedge funds and other institutional investors own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.